Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

- this pilot study will assess the safety and tolerability of combining enzalutamide with
an gonadotropin-releasing hormone agonist (GnRH) and external beam radiation

- Correlative imaging and tissue biopsy analysis will be performed to assess the
radiographic response to enzalutamide plus gonadotropin-releasing hormone agonist (GnRH)
therapy as well as intratumoral androgen signaling

Inclusion Criteria:

- histologically proven adenocarcinoma of the prostate within 6 months of screening

- Eastern Cooperative Oncology Group(ECOG) score 0-2

- adequate organ and and blood marrow function

- must be a candidate for long-term androgen deprivation in combination with external
beam radiation for the treatment of high risk prostate cancer

- patient must permit a targeted prostate biopsy at the time of study initiation or at
the beginning of radiation treatment

- men who are sexually active with female partners of child-bearing potential mush agree
to use adequate contraception

Exclusion Criteria:

- prior treatment with agents known to have endocrine effects on prostate cancer

- treatment with corticosteroids within 4 weeks of enrollment

- treatment with androgens within 6 months of enrollment

- may not be receiving any other investigational agents

- Prostate specific antigen greater than 160ng/dL

- history of malignancy( other than non-melanoma skin cancer) within 5 years

- uncontrolled intercurrent illness

- cardiovascular event within 6 months of enrollment

- seizure or seizure disorder history

- contraindications to MRI- pacemakers, clips, etc